Phase 3
Completed N=87
Remdesivir for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)
Source: ClinicalTrials.gov NCT06729593 ↗Enrolled (actual)
87
Serious AEs
12.6%
Results posted
Oct 2025
Primary outcomePrimary: Number of Participants With a 6-category Primary Ordinal Outcome (Recovery) at Day 90 — 5; 8; 7; 6 Participants — p=0.96
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
This study looks at the safety and effectiveness of Remdesivir in treating COVID-19 in people who have been hospitalized with the infection and who have acute respiratory failure. Participants in the study will be treated with Remdesivir plus current standard of care (SOC), or with placebo plus current SOC.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With a 6-category Primary Ordinal Outcome (Recovery) at Day 90 |
5; 8; 7; 6; 4; 5 | 0.96 |
| SECONDARY Number of Participants Who Died Through Day 90 |
17; 20 | 0.37 |
| SECONDARY Number of Participants With a Safety Outcome Through Day 5 |
25; 25 | 0.80 |
| SECONDARY Number of Participants With a Safety Outcome Through Day 28 |
36; 34 | 0.88 |
| SECONDARY Number of Participants Who Died Through Day 180 |
19; 21 | 0.50 |
Eligibility Criteria
Inclusion Criteria
Refer to the master protocol (NCT04843761)
Exclusion Criteria
Refer to the master protocol (NCT04843761)
Additional Exclusion Criteria:
- Prior receipt of any dose of remdesivir during the present illness
- GFR (glomerular filtration rate) 10 times upper limit of normal
- Unwillingness to commit to avoid sex that may result in pregnancy for at least 7 days after completion of remdesivir vs. placebo
Data sourced from ClinicalTrials.gov (NCT06729593). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.